



HAL
open science

Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses

Juliette Ferlin, Rayan Farhat, Sandrine Belouzard, Laurence Cocquerel, Antoine Bertin, Didier Hober, Jean Dubuisson, Yves Rouillé

► To cite this version:

Juliette Ferlin, Rayan Farhat, Sandrine Belouzard, Laurence Cocquerel, Antoine Bertin, et al.. Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses. *Journal of General Virology*, 2018, 99 (8), pp.1086-1096. 10.1099/jgv.0.001099 . hal-02113930

HAL Id: hal-02113930

<https://hal.science/hal-02113930>

Submitted on 29 Apr 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Title: Investigation of the role of GBF1 in the replication of positive-sense single-**
2 **stranded RNA viruses**

3

4 **Authors:** Juliette Ferlin¹, Rayan Farhat^{1,*}, Sandrine Belouzard¹, Laurence Cocquerel¹,
5 Antoine Bertin², Didier Hober², Jean Dubuisson¹ and Yves Rouillé¹

6

7 **Affiliations:** ¹ Center for Infection & Immunity of Lille, Inserm U1019, CNRS UMR-8204,
8 Institut Pasteur de Lille, Université de Lille, Lille, France

9 ² Université de Lille, Faculté de Médecine, CHU Lille, Laboratoire de Virologie EA3610,
10 Lille, France

11

12 **Correspondence:** Yves Rouillé, yves.rouille@ibl.cnrs.fr

13

14 *present address: Inserm U1052, Cancer Research Center of Lyon (CRCL), Université de
15 Lyon (UCBL1), CNRS UMR-5286, Centre Léon Bérard, Lyon, France

16

17 **Keywords:** ADP-ribosylation factor, hepatitis C virus, coxsackievirus B4, human coronavirus
18 229E, Sindbis virus, yellow fever virus

19

20 **Subject category:** Animal viruses – positive-strand RNA

21

22 **Word counts:** abstract: 223; body of text: 5047

23

24 **Abbreviations:** Arf, ADP ribosylation factor; BFA, brefeldin A; BIG, brefeldin A-inhibited
25 guanine nucleotide-exchange protein for ADP ribosylation factor; CRISPR-Cas9, clustered
26 regularly interspaced short palindromic repeats-CRISPR associated protein 9; COP-I, coat
27 protein complex I; CVB4, coxsackievirus B4; DMEM, Dulbecco's modified Eagle's medium;
28 GBF1, golgi brefeldin A resistant guanine nucleotide exchange factor 1; GCA, golgicide A;
29 GEF, guanine nucleotide-exchange factor; HCV, hepatitis C virus; HCoV-229E, human
30 coronavirus 229E ; hpi, hour(s) post infection; KO, knockout; MTS, 3-(4,5-dimethylthiazol-
31 2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; SINV, Sindbis virus;
32 VLDL, very low density lipoprotein, YFV, yellow fever virus.

33

34 **ABSTRACT**

35 GBF1 has emerged as a host factor required for the replication of positive-sense single-
36 stranded RNA viruses of different families, but its mechanism of action is still unknown.
37 GBF1 is a guanine-nucleotide exchange factor for Arf family members. Recently, we
38 identified Arf4 and Arf5 (class II Arfs), as host factors required for the replication of hepatitis
39 C virus (HCV), a GBF1-dependent virus. To assess if a GBF1/class II Arfs pathway is
40 conserved among positive-sense single-stranded RNA viruses, we investigated yellow fever
41 virus (YFV), Sindbis virus (SINV), coxsackievirus B4 (CVB4) and human coronavirus 229E
42 (HCoV-229E). We found that GBF1 is involved in the replication of these viruses. However,
43 using siRNA or CRISPR-Cas9 technologies, the depletion of Arf1, Arf3, Arf4 or Arf5 had no
44 impact on viral replication. In contrast, the depletion of Arfs pairs suggested that class II Arfs
45 could be involved in HCoV-229E, YFV and SINV infection, as for HCV, but not in CVB4
46 infection. In addition, another Arf pair, Arf1 and Arf4, appears essential for YFV and SINV
47 infection, but not for other viruses. Finally, CVB4 infection was not inhibited by any
48 combination of Arf depletion. We conclude that the mechanism of action of GBF1 in viral
49 replication appears not to be conserved, and that a subset of positive-sense single-stranded
50 RNA viruses from different families might require class II Arfs for their replication.

51

52 INTRODUCTION

53 Positive-sense, single-stranded RNA viruses ((+)RNA viruses) replicate their genome in the
54 cytoplasm of their host cell. Their RNA-dependent RNA polymerase and other non-structural
55 proteins implicated in the replication are found in association with cellular membranes. For a
56 number of (+)RNA viruses, intracellular membranes of the host cells are rearranged during
57 replication and viral replication complexes are associated with these membrane
58 rearrangements. The morphology and origin of these membrane rearrangements appear to
59 vary for different viruses. However, it is possible that some conserved cellular pathways are
60 redirected during the replication of different viruses for the formation and functioning of these
61 membranous replication complexes.

62 GBF1 has recently emerged as a host factor involved in the replication of (+)RNA viruses of
63 the *Picornaviridae* [1-3], *Coronaviridae* [4], *Flaviviridae* [5,6] and *Hepeviridae* [7] families.

64 GBF1 is a brefeldin A (BFA)-sensitive guanine nucleotide exchange factor (GEF) of Arf
65 family members [8]. Through Arf1 activation, it participates to the regulation of COP-I-
66 dependent vesicular transport, phospholipid metabolism, actin cytoskeleton dynamics at the
67 Golgi, and lipid droplet metabolism [9,10]. GBF1 has 6 conserved domains [11]. Its Arf-GEF
68 activity is catalyzed by the Sec7 domain and is selective for class I Arfs (Arf1-3) and class II
69 Arfs (Arf4 and Arf5) [8,12]. The functions of the other conserved domains are less defined
70 [11,13].

71 Little is known about the mechanism of action of GBF1 in viral infections. Its Arf-GEF
72 activity appears to be of special importance at the onset of the replication of different viruses
73 [4-7]. Accordingly, GBF1 is temporally recruited to replication complexes at early times of
74 poliovirus replication, but not later on [14]. However, its Arf-GEF activity is not required for
75 the formation of replication complexes-associated membrane rearrangements [1,4,5],
76 suggesting that GBF1 is rather involved in a post-formation step of membrane-associated

77 replication complexes. It has been proposed that GBF1 function in viral infections could be
78 related to the regulation of COP-I, a molecular machinery involved in intracellular transport,
79 which has also been reported to be required for the replication of several (+)RNA viruses [15-
80 19]. GBF1 regulates COP-I vesicle formation by stimulating COP-I recruitment to Golgi
81 membranes through Arf1 activation in a BFA-sensitive manner [9,10]. By analogy, the BFA
82 sensitivity of viral replication has been viewed as an argument for Arf1 involvement. In
83 support to this hypothesis, Arf1 [20], or both Arf1 and Arf3 [3] are activated during
84 enterovirus infection, and siRNA-mediated depletion of Arf1 [4,21] or of both Arf1 and Arf3
85 [3] impairs the replication of diverse (+)RNA viruses. However, an experimental
86 demonstration of the existence of a GBF1-Arf1-COP-I pathway involved in viral replication
87 is still lacking. During poliovirus infection, GBF1 is transiently recruited to replication
88 complexes, but this recruitment is not coupled to COP-I recruitment [14]. Moreover, during
89 poliovirus replication, GBF1 function does not depend on its catalytic Sec7 domain and
90 therefore on its Arf-GEF activity [22], indicating a mechanism of action unrelated to Arf1
91 activation.

92 We previously showed that GBF1 is critical to the replication of hepatitis C virus (HCV) [5],
93 and that its Arf-GEF activity is essential for regulating HCV replication [23]. However, GBF1
94 function in HCV replication is not mediated by Arf1, and is distinct from its regulatory
95 functions of the cellular secretory pathway and of the morphology of the Golgi complex, two
96 cellular processes that are mediated by COP-I. We found that different pairs of Arf proteins
97 are involved in these two functions of GBF1. The Arf1/Arf4 pair is involved in the regulation
98 of the secretory pathway and the Arf4/Arf5 pair in the replication of HCV [23]. In this study
99 we compared the requirement of Arfs for the replication of a series of GBF1-dependent
100 (+)RNA viruses from different families.

101

102

103 **RESULTS**

104 **BFA sensitivity of (+)RNA viruses**

105 To probe for GBF1 dependency, we made use of BFA, which inhibits GBF1 and two related
106 Arf-GEFs, named BIG1 and BIG2. In addition to HCV, we selected viruses from different
107 families of (+)RNA viruses, namely yellow fever virus (YFV, *Flaviviridae*), human
108 coronavirus 229E (HCoV-229E, *Coronaviridae*), coxsackievirus B4 (CVB4, *Picornaviridae*),
109 and Sindbis virus (SINV, *Togaviridae*). We also included human adenovirus-5, a DNA virus,
110 as a negative control. Cells were infected in the presence of increasing doses of BFA. To
111 avoid cell toxicity, BFA treatment was restricted to 8 hours of contact, when the infection was
112 scored later than 8 hours post-infection (hpi) (adeno, HCoV-229E, YFV, HCV). As
113 previously shown [5], adenovirus was not inhibited by BFA. In contrast, all RNA viruses
114 tested were sensitive to treatment with 0.1 to 10 $\mu\text{g/ml}$ BFA in a dose-dependent manner (fig.
115 1a). However, the extent of inhibition was different between viruses. When comparing the
116 inhibition of infection at 1 $\mu\text{g/ml}$ BFA, CVB4 and HCoV-229E appeared the most sensitive
117 viruses (~99% inhibition) and SINV the least one (62% inhibition), HCV and YFV having
118 intermediate sensitivities (~97% and ~88% inhibition, respectively). It is noteworthy that this
119 difference of sensitivity between viruses is only visible in the amplitude of the inhibitory
120 response, but not in the range of inhibitory doses of BFA. For all viruses, the first inhibitory
121 dose was 0.1 $\mu\text{g/ml}$. No inhibition could be observed with 0.01 $\mu\text{g/ml}$ BFA for any virus.
122 Such a similar range of inhibitory doses observed with all RNA viruses suggests a similar
123 mode of action of BFA against all these viruses.

124 An MTS assay was performed to quantify the impact of BFA toxicity on Huh-7 cells (fig. 1b).

125 Two protocols were used to assess different protocols of infection. The assay was performed
126 either after 6 hours of contact in the presence of BFA, or after 8 hours of contact followed by

127 22 hours without BFA. These two protocols correspond to the shortest (CVB4 and SINV) and
128 longest (HCV) infection periods used for quantifying BFA inhibition of viral infections. The
129 only experimental condition showing an inhibition of cell growth or metabolism was with 8
130 hours incubation with 10 $\mu\text{g/ml}$ BFA, followed by 22 hours without BFA. However, the
131 decrease was not in the same proportion as viral infection inhibitions measured in the same
132 condition. With 1 $\mu\text{g/ml}$ BFA, the inhibition of cell growth was minimal ($\sim 20\%$ decrease),
133 whereas the inhibition of viral infections was close to maximal. These results, together with
134 the absence of inhibition of adenovirus infection, indicate that the inhibition of (+)RNA
135 viruses infections could not be explained by BFA toxicity.

136

137 **GBF1 dependency of (+)RNA viruses**

138 Because GBF1 is not the only target of BFA, we also assessed the impact of BFA on viral
139 infections in R1 cells. R1 cells are Huh-7-derived cells that have a point mutation in one copy
140 of the GBF1 gene [24]. This mutation replaces the methionine residue 832 in the catalytic
141 Sec7 domain by a leucine, a substitution that dramatically decreases BFA binding to GBF1
142 [25]. Since the two other BFA-sensitive Arf-GEFs, BIG1 and BIG2, are not mutated in R1
143 cells, any effect of a BFA treatment can be attributed to the inhibition of BIG1 and/or BIG2,
144 but not of GBF1. Inversely, an action of BFA in Huh-7 cells that is not reproduced in R1 cells
145 indicates an involvement of GBF1. We infected R1 cells in the presence of BFA and
146 quantified infections as we did before in Huh-7 cells. A ~ 100 fold decrease of BFA sensitivity
147 of all viral infections was observed (fig. 2a). The only inhibitory dose was 10 $\mu\text{g/ml}$, and its
148 impact on infections was similar to that observed with 0.1 $\mu\text{g/ml}$ in Huh-7 cells. This shift in
149 BFA sensitivity between R1 and parental Huh-7 cells indicates an involvement of GBF1 in
150 viral infections.

151 To further assess the importance of GBF1 in the infection of BFA-sensitive RNA viruses, we
152 used golgicide A (GCA), which is a specific inhibitor of GBF1, with no action on other BFA
153 targets [26]. GCA inhibited all BFA-sensitive viruses (fig. 2b), confirming that the observed
154 inhibition of infection by BFA was only due to its action on GBF1. Again, CVB4 and HCoV-
155 229E were the two most affected viruses. As for BFA treatments, a small decrease in cell
156 growth was also observed with an 8-hour treatment with GCA followed by 22 hours with no
157 inhibitor and, to a lesser extent, with a 6-hour treatment (fig. 2c). These results confirm the
158 implication of GBF1 in the infection of all RNA viruses tested in this study.

159 We next investigated which step of the viral life cycle is affected by GBF1 inhibition. GBF1
160 was previously shown to be involved in a post-entry step of the HCV life cycle [5]. CVB4
161 and HCoV-229E, the two viruses the most affected by BFA, were investigated. To test GBF1
162 involvement during virus entry, BFA was added to cells during virus contact and removed
163 post-entry. To test GBF1 involvement at a post-entry step, cells were infected in the absence
164 of BFA, and BFA was added during 6 hours after virus removal. For both viruses, the
165 infection was inhibited when BFA was present at the post-entry step, but much less affected
166 when BFA was present at the entry step (fig. 3). These results indicated that GBF1 is likely
167 involved in a post-entry step of the life cycle of these (+)RNA viruses.

168

169 **Involvement of Arf family members in the infection of (+)RNA viruses**

170 We next assessed if the requirement of GBF1 for (+)RNA virus infection translated into an
171 involvement of Arfs. Arf proteins potentially regulated by GBF1 and sensitive to BFA and
172 GCA, namely Arf1, Arf3, Arf4 and Arf5 (human cells have no Arf2), were depleted with
173 pools of synthetic siRNAs. The extent and the specificity of depletion were evaluated using a
174 set of antibodies specific for each Arf protein (fig. 4a). Each siRNA pool specifically depleted
175 the targeted protein with minimal impact on the expression of other Arfs (fig. 4b), except for

176 two effects: Arf4 was overexpressed in cells depleted of Arf1, and Arf3 expression was
177 slightly reduced in cells depleted of Arf4 (fig. 4c). Arf4 overexpression in Arf1-depleted cells
178 was previously detected at the mRNA level [23], suggesting that these two Arf proteins are
179 functionally linked. Other variations of expression levels appeared non-significant.

180 When siRNA-treated cells were infected, an inhibition of infection of approximately 10-30%
181 was measured for all viruses and for all Arf proteins (fig. 4d), except for CVB4, which was
182 not impacted by Arf4 and by Arf5 depletions. The inhibition of HCoV-229E and HCV
183 infection imposed by Arf1, Arf4 and Arf5 siRNAs appeared significant, but most of the other
184 inhibitions were not. Such a moderate and non-specific inhibition of infection in cells
185 depleted of each Arf protein was previously observed with HCV [23]. When Huh-7 cells were
186 depleted of two Arf proteins simultaneously, two pairs of siRNA pools induced an inhibition
187 of infection larger than the ones observed with single depletions (fig. 4e). SINV and YFV
188 infections were inhibited by the depletion of Arf1 and Arf4 (80% and 92% inhibition,
189 respectively). In addition, HCV, SINV and YFV infections were inhibited in cells
190 simultaneously depleted of Arf4 and Arf5 (61%, 70% and 54% inhibition, respectively).
191 HCoV-229E infection also appeared to be reduced in cells depleted of this pair of Arfs, but
192 the inhibition was less dramatic (43% inhibition). In addition, similar inhibitions were also
193 observed with other Arf pairs for this virus. These inhibitions of infection were not correlated
194 to a loss of viability of the cells (fig. 4f). It is noteworthy that CVB4 infection was not
195 strongly affected by any Arf pair depletion. This lack of inhibition was confirmed by
196 immunoblot analysis of VP1 expression (fig. 4g).

197 To confirm the results obtained using siRNAs, we used CRISPR-Cas9 technology to generate
198 knockout (KO) cells. One Arf4KO, one Arf5KO and three Arf1KO cell lines were generated.
199 To avoid biases resulting from the use of clones, we used the whole population of cells
200 transfected with CRISPR-Cas9 constructs in each case. A small amount of residual expression

201 of targeted proteins of 0 to 20% was measured for each cell line (fig. 5a). This residual
202 expression likely resulted from the presence of a small amount of cells expressing the targeted
203 protein. No major impact on the expression of other Arfs was observed, except for a slight
204 decrease in Arf5 expression in the Arf1KO cell line 1.3, which was not observed for the two
205 other Arf1KO cell lines (fig. 5b).

206 ArfKO cell lines were infected with HCoV-229E, HCV, SINV or YFV, the four viruses
207 impacted in siRNA experiments. The infections of these four viruses were marginally affected
208 in the three Arf1KO cell lines. They were inhibited by 20-30% in the Arf5KO cell line 5.1. In
209 the Arf4KO cell line 4.1, HCV infection was inhibited by 20% and the infections by HCoV-
210 229E, SINV and YFV were inhibited by ~50% (fig. 5c). These results confirmed the lack of
211 inhibition of HCV infection by any single Arf depletion, and revealed an importance of Arf4
212 in HCoV-229E, SINV and YFV infections that was not detected in siRNA experiments.

213 We next tried to generate double KO cell lines by transfecting Arf4 CRISPR-Cas9 constructs
214 in the Arf5KO cell line or Arf5 CRISPR-Cas9 constructs in the Arf4KO cell line.
215 Unfortunately, most cells died during the selection, and the few surviving cells turned out not
216 to be double KO (data not shown). This indicates that a permanent invalidation of both class
217 II Arf genes is lethal for Huh-7 cells. Therefore, we used siRNAs to transiently deplete Arf
218 proteins in ArfKO cell lines. Again, we observed a strong toxicity of siRNAs to Arf1 or to
219 Arf5 transfected in the Arf4KO cell line. On the other hand, Arf4 depletion by siRNA
220 transfection was also toxic in Arf1KO cells, but not in Arf5KO cells. An MTS assay
221 confirmed the absence of toxicity of Arf4 siRNA transfection in the Arf5KO cell line 5.1 (fig.
222 6a).

223 Therefore, we used this experimental setup (siRNA-mediated depletion of Arf4 in Arf5KO
224 cells) to confirm the importance of the pair of class II Arfs in viral infections. As controls, we
225 used a non-targeting siRNA, as for experiments in parental Huh-7 cells, and also the Arf5

226 siRNA pool, which should have no impact in Arf5KO cells. As a control cell line, we used a
227 cell line selected after transfection of a CRISPR-Cas9 construct expressing no guide RNA.
228 The depletion of Arf4 and Arf5 was confirmed by immunoblotting (fig. 6b). Arf5 was
229 undetectable in cells transfected with Arf5 siRNA and in Arf5KO cells, and was not affected
230 by the depletion of Arf4 in control cells. Arf4 expression was reduced to ~30% in both cell
231 lines after transfection of Arf4 siRNA.

232 siRNA-transfected control and Arf5KO cells were infected with HCoV-229E, HCV, SINV
233 and YFV. As expected from results of previous double depletions by siRNA, HCoV-229E,
234 HCV and SINV infections were strongly inhibited (85%, 89% and 83% inhibition,
235 respectively) (fig. 6c). In contrast, YFV infection was less impacted (53% inhibition). In all
236 other conditions, viral infections were inhibited by less than 40%, except in Arf5KO cells
237 transfected with Arf5 siRNAs, which surprisingly displayed an inhibition of almost 50% of
238 HCV and SINV infections, likely resulting from off-target effects. All together, these results
239 confirmed the importance of class II Arfs for infection by HCV [23] and by HCoV-229E,
240 SINV and YFV, as previously observed with double siRNAs transfection-based experiments.

241

242 **DISCUSSION**

243 In this study, we investigated whether the function of class II Arfs is conserved in infections
244 of GBF1-dependent (+)RNA viruses. GBF1 has been reported to be required for the
245 replication of different viruses, but its function is still not understood. Recently, we found that
246 the function of GBF1 in HCV replication differs from its function in the early secretory
247 pathway [24]. Whereas the effect of GBF1 inhibition or depletion on the secretion of albumin
248 and VLDL and on the Golgi morphology is phenocopied by simultaneously depleting both
249 Arf1 and Arf4, the depletion of this pair of Arfs has no impact on HCV infection [23]. In
250 contrast, the impact of GBF1 inhibition or depletion on HCV replication is phenocopied by

251 the depletion of another pair of Arfs. HCV replication is specifically inhibited by
252 simultaneously depleting Arf4 and Arf5. Interestingly, the depletion of this pair of Arfs has
253 no impact on the secretion of albumin or VLDL. Cells depleted of Arf4 and Arf5 accumulate
254 enlarged lipid droplets, suggesting a function related to the regulation of lipid metabolism or,
255 at least, to the morphology of these organelles, which are known to depend on GBF1 for their
256 metabolism [9,10]. Therefore, different GBF1 functions appear to be mediated by different
257 pairs of Arfs. This is in line with a previous report that the depletion of different Arf pairs
258 results in different specific phenotypes on secretory and endosomal compartments [27], which
259 are collectively observed upon BFA treatment of the cells. All these observations suggest that
260 different pairs of Arfs could mediate the different cellular functions that are regulated by
261 GBF1, BIG1 and BIG2, the three BFA-sensitive Arf-GEFs.

262 The function of the class II Arf pair in virus infection appears to be partly conserved among
263 viruses from different families. Their simultaneous depletion inhibited infection by HCV,
264 HCoV-229E, SINV and YFV, but not by CVB4. Interestingly, all these viruses also depend
265 on GBF1 for their replication, suggesting the existence of a GBF1-Arf4/5 pathway
266 requirement for some but not all (+)RNA viruses. These inhibitions were also observed to
267 some extent with the Arf4KO but not the Arf5KO cell line, suggesting a major importance of
268 Arf4, which had not been observed with siRNA-mediated depletions of individual Arf
269 proteins.

270 We also tried to confirm the contribution of class II Arfs with double KO cells. Unfortunately,
271 the double KO was not viable, when each single KO was, suggesting that class II Arfs
272 collectively fulfil a vital function in Huh-7 cells. We also observed a great reduction of
273 viability in Arf4KO cells transfected with Arf5 siRNA. Nevertheless, the siRNA-mediated
274 depletion of Arf4 in Arf5KO cells turned out to be not toxic. This difference probably
275 resulted from a less pronounced down-regulation imposed by Arf4 siRNA, than by Arf5

276 siRNA. Therefore, the transfection of Arf4 siRNA in Arf5KO cells probably resulted in
277 residual Arf4 expression levels compatible with cell survival. This allowed us to confirm the
278 inhibition of HCV, HCoV-229E, SINV and YFV infections in cells depleted of both class II
279 Arfs. Class II Arfs were previously reported to be implicated in the dengue virus life cycle,
280 and more precisely in the assembly/secretion step, but the replication step was not
281 investigated [28]. It would have been interesting to confirm that the depletion of class II Arfs
282 actually affects the replication step of the life cycle of HCoV-229E, SINV and YFV, as it
283 does for HCV [23]. Unfortunately, we do not have the tools to address this question.
284 Nevertheless, we have shown that GBF1 is implicated in HCV replication [5] and in a post-
285 entry step of the life cycle of HCoV-229E and CVB4 (this study).

286 In addition to the Arf4/Arf5 pair, YFV and SINV were also sensitive to the simultaneous
287 depletion of Arf1 and Arf4. As this Arf pair is involved in the regulation of the secretory
288 pathway [23,27], this suggests an involvement of this pathway in the life cycle of these
289 viruses. Currently, we do not know which step of their life cycle is actually impacted by the
290 depletion of this Arf pair. An entry inhibition can be hypothesized, resulting from a default of
291 expression of specific receptors at the cell surface. Alternatively, we cannot rule out the
292 possibility of an inhibition of the replication step. The Arf1/Arf4 pair has been previously
293 reported to be involved in the localization of the capsid protein to lipid droplets in dengue
294 virus-infected cells [29].

295 In contrast, CVB4 infection was not inhibited in cells depleted of both Arf4 and Arf5, nor of
296 any other Arf pair, although it was inhibited by BFA in a GBF1-dependent manner. This
297 suggests that the function of GBF1 in CVB4 infection could be unrelated to its Arf-GEF
298 activity. Previously, a study by Lanke et al. demonstrated the implication of GBF1, but could
299 not find any implication of Arfs, in the replication of CVB3 [2]. A sec7-independent GBF1
300 function has also been reported for poliovirus infection [22]. In contrast, the replication of

301 enterovirus 71 has been reported to depend on the pair of class I Arfs, Arf1 and Arf3 [3].
302 Further studies will be necessary to assess if CVB4, and more generally which other
303 enteroviruses use a Sec7-independent function of GBF1 and what is the mechanism of action.
304 In conclusion, this study confirms and extends the implication of class II Arfs in the infection
305 of different (+)RNA viruses. Cellular pathways specifically controlled by class II Arfs are
306 currently unknown. Arf4 has been proposed to be part of a Golgi stress-response pathway
307 [30]. This function of Arf4 requires GBF1, but is not linked to Arf5. Collectively, class II
308 Arfs are not involved in the regulation of the secretory pathway [23,27]. They fulfil a vital
309 function in Huh-7 cells, and they also appear to be involved in regulating the morphology of
310 lipid droplets. However, we still do not know whether these two functions are related to each
311 other. Future work is required to decipher pathways specifically regulated by class II Arfs and
312 to identify effectors implicated in these pathways, which could be interesting new targets for
313 developing antiviral therapies.

314

315

316 **METHODS**

317 **Reagents.** Dulbecco's modified Eagle's medium (DMEM), phosphate-buffered saline (PBS)
318 and 4',6-diamidino-2-phenylindole (DAPI) were purchased from Life Technologies. Goat and
319 fetal calf sera (FCS) were from Eurobio. Golgicide A and Mowiol 4-88 were from
320 Calbiochem. Protease inhibitors cocktail (Complete) was from Roche. Other chemicals were
321 from Sigma.

322 **Antibodies.** Mouse anti-HCV E1 mAb A4 [31] and mouse anti-YFV E mAb 2D12 (anti-E,
323 ATCC CRL-1689) were produced in vitro by using a MiniPerm apparatus (Heraeus). Mouse
324 anti-enterovirus VP1 mAb (clone 5-D8/1) was from DAKO. Mouse anti-Arf1 mAb 1A9/5
325 was from Santa Cruz Biotechnology. Mouse anti-Arf3 mAb was from BD Biosciences.

326 Rabbit anti-human Arf4 mAb EPR12133B was from Abcam. Mouse anti-Arf5 mAb 1B4 was
327 from Abnova. Mouse anti- β -tubulin mAb TUB 2.1 was from Sigma. Mouse anti-GFP mAb
328 was from Roche. Peroxidase-conjugated secondary antibodies and cyanine 3-conjugated goat
329 anti-mouse IgG were from Jackson Immunoresearch.

330 **Cell culture.** Huh-7 [32] and R1 [24] cells were grown at 37°C in Dulbecco's modified
331 Eagle's medium (DMEM), high glucose modification, supplemented with glutamax-I and
332 10% FCS.

333 **HCV.** The virus JFH1-CSN6A4 used in this study was produced as previously described [5].
334 For infection assays, cells were infected for 2 hours at 37°C, and fixed with cold methanol at
335 30 hpi.

336 **Adenovirus.** A recombinant defective adenovirus expressing a green fluorescent protein
337 (GFP) was as previously described [24]. Cells were infected for 1 hour at 37°C, and fixed for
338 20 minutes with PFA 3% at 16 hpi.

339 **SINV.** A recombinant Sindbis virus expressing HCV E1 glycoprotein was as previously
340 described [33]. Cells were infected for 1 hour at 37°C, and fixed with cold methanol at 6 hpi.

341 **YFV.** Yellow fever virus strain 17D was obtained from Dr Philippe Desprès (Institut Pasteur
342 de Paris). Cells were infected for 1 hour at 37°C, and fixed with PFA 3% at 24 hpi.

343 **HCoV-229E.** A recombinant human coronavirus 229E expressing GFP [34] was provided by
344 Dr Volker Thiel (University of Bern, Swiss). Cells were infected for 1 hour at 37°C, and fixed
345 with PFA 3% at 12 hpi.

346 **CVB4.** Coxsackievirus B4 strain E2 (CVB4) was previously provided by Dr Ji-Won Yoon
347 (Julia McFarlane Diabetes Research Center, Calgary, Alberta, Canada). CVB4 suspensions
348 were prepared and titred as described [35]. Cells were infected for 1 hour at 37°C, and fixed
349 with cold methanol at 6 hpi.

350 ***Infection assays.*** Huh-7 cells grown on glass coverslips or in 96-well plates were incubated
351 at 37°C for 1 or 2 hours (depending on the virus) in the presence of the virus. For each virus,
352 the viral stocks were diluted so as to obtain 20 to 40% of infected cells in control conditions.
353 Cells were fixed at a time that allows for a clear detection of infected cells vs. non-infected
354 cells, and avoids the detection of reinfection events, thus limiting the analysis to a single
355 round of infection. Cells were fixed for 20 min with 3% PFA or for 1 min with cold methanol
356 at -20°C. Cells were then rinsed with PBS and processed for immunofluorescence as
357 previously described [36] using specific primary mouse antibodies to HCV E1 (for both HCV
358 and SINV), YFV E, GFP (for HCoV-229E) or VP1 (for CVB4) followed by a cyanine-3-
359 conjugated goat anti-mouse IgG secondary antibody for the detection of infected cells. Nuclei
360 were stained with DAPI. Immunostained cells were observed with a Zeiss Axiophot
361 microscope equipped with a 10×-magnification objective. Fluorescent signals were collected
362 with a Coolsnap ES camera (Photometrix). For each well or coverslip, a series of images of
363 randomly picked areas were automatically recorded using the Metamorph software. Cells
364 labeled with anti-virus mAbs were counted as infected cells. The total number of cells was
365 obtained from DAPI-labeled nuclei. Infected cells and nuclei were automatically counted
366 using a macro written in the ImageJ software. Infections were scored as the ratio of infected
367 over total cells. Data are presented as the percentage of infection relative to the control
368 condition.

369 ***Drug treatments.*** BFA and GCA were dissolved in DMSO, aliquoted and kept at -20°C. For
370 infection assays with SINV and CVB4, cells were incubated with BFA or GCA at the
371 indicated concentrations during virus inoculation and up to 6 hpi. For infection assays with
372 HCV, YFV, adenovirus and HCoV-229E, cells were incubated with BFA or GCA at the
373 indicated concentrations during virus inoculation and up to 8 hpi. The medium was then

374 removed; the cells were rinsed twice with PBS and returned to a drug-free medium until the
375 end of the assay. For each experiment, a control condition with DMSO was included.

376 **RNA interference.** RNA interference experiments were performed as previously described
377 [23]. siRNAs were obtained from Dharmacon. For Arf3, Arf4 and Arf5, pools of 4 siRNA
378 were used. For Arf1, a mix of 2 individual siRNAs (J-011580-05-0005 & J-011580-08-0005)
379 was used to avoid off-target effects resulting from the use of the pool of 4 siRNAs [23]. The
380 control siRNA was the non-targeting siRNA #1 (D-001810-01-20). Briefly, cells were
381 transfected with siRNAs at 20 nM using lipofectamine RNAi MAX (Life Technologies). The
382 cells were passed the day after and infected at 3 days post-transfection.

383 **Generation of knock out cells.** Arf genes were invalidated in Huh-7 cells using the CRISPR-
384 Cas9 technology. Guide RNA sequences were selected with the help of the CRISPR design
385 tool at <http://crispr.mit.edu/> and inserted into pX330-U6-Chimeric_BB-CBh-hSpCas9, a gift
386 from Feng Zhang (Addgene plasmid # 42230). Selected target sequences for sgRNA design
387 were CTTAAGCTTGTAGAGGATCG for Arf1.1, GATCCTCTACAAGCTTAAGC for
388 Arf1.2, ATCCTCTACAAGCTTAAGCT for Arf1.3, GGAGATAGTGAGGCCCATGG for
389 Arf4.1 and GAAGATCCGCGAAAAGAGCG for Arf5.1 KO cell lines. Constructs were
390 generated as described [37]. Sub-confluent Huh-7 cells grown in 6-well plates were
391 transfected with 1 μ g of CRISPR-Cas9 construct and 50 ng of pPuro using the TransIT-LT1
392 transfection reagent (Mirus). Two days later, transfected cells were selected with puromycin
393 at 5 μ g/ml during 4 days. The puromycin-containing medium was renewed every day. After 4
394 days of selection, almost all the cells from control transfections with no pPuro plasmid were
395 dead. Selected cells were then expanded in puromycin-free medium. The residual expression
396 of targeted protein was measured using immunoblotting.

397 **Immunoblotting.** Cells were rinsed 3 times with cold PBS, and lysed at 4°C for 20 min in a
398 buffer containing 50 mM TrisCl, pH 7.5, 100 mM NaCl, 2 mM EDTA, 1% Triton- X, 0.1%

399 SDS, 1 mM PMSF, and a mix of protease inhibitors. Insoluble material was removed by
400 centrifugation at 4°C. The protein content was determined using a bicinchoninic acid assay
401 (Sigma). The proteins were then resolved by SDS-PAGE and transferred onto nitrocellulose
402 membranes (Hybond-ECL; Amersham) using a Trans-Blot apparatus (Bio-Rad). Proteins of
403 interest were revealed with specific primary antibodies, followed by species-specific
404 secondary antibodies conjugated to peroxidase. Proteins were visualized using enhanced
405 chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate from Thermofischer
406 Scientific). The signals were recorded using a LAS 3000 apparatus (Fujifilm). Quantification
407 of unsaturated signals was carried out using the gel quantification function of ImageJ.

408 **Viability assay.** An MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
409 sulfophenyl)-2H-tetrazolium]-based viability assay (CellTiter 96 aqueous nonradioactive cell
410 proliferation assay from Promega) was conducted as recommended by the manufacturer using
411 sub-confluent cell cultures grown in 96-well plates.

412 **Statistical analysis.** Statistical analysis was performed using the software Prism. The
413 significance between groups was determined by one-way ANOVA and a Dunnett post-hoc
414 test. Only significant p-values are indicated by the asterisks above the graphs.

415

416

417 **AUTHOR STATEMENTS**

418 **Funding information:** This work was supported in part by the French ‘Agence Nationale de
419 Recherche sur le Sida et les hépatites virales’ (ANRS). JF was supported by a pre-doctoral
420 fellowship from ANRS.

421

422 **Acknowledgements:** The authors thank Dr Philippe Desprès, Dr Volker Thiel and Dr Feng
423 Zhang for providing us with viruses and plasmid. Some data were generated with the help of
424 the imaging core facility of the Institut Pasteur de Lille (BICeL).

425

426 **Conflicts of interest:** The authors declare that no conflict of interest exists

427

428

429 **REFERENCES**

430

- 431 1. **Belov GA, Feng Q, Nikovics K, Jackson CL, Ehrenfeld E.** A critical role of a
432 cellular membrane traffic protein in poliovirus RNA replication. *PLoS Pathog.* 2008
433 Nov 1;4:e1000216.
- 434 2. **Lanke KHW, van der Schaar HM, Belov GA, Feng Q, Duijsings D, et al.** GBF1, a
435 guanine nucleotide exchange factor for Arf, is crucial for coxsackievirus B3 RNA
436 replication. *J Virol.* 2009;83:11940–11949.
- 437 3. **Wang J, Du J, Jin Q.** Class I ADP-Ribosylation Factors Are Involved in Enterovirus
438 71 Replication. Zheng Z-M, editor. *PLoS ONE.* 2014;9(6):e99768.
- 439 4. **Verheije MH, Raaben M, Mari M, Lintelo te EG, Reggiori F, et al.** Mouse hepatitis
440 coronavirus RNA replication depends on GBF1-mediated ARF1 activation. *PLoS*
441 *Pathog.* 2008;4:e1000088.
- 442 5. **Goueslain L, Alsaleh K, Horellou P, Roingeard P, Descamps V, et al.** Identification
443 of GBF1 as a cellular factor required for hepatitis C virus RNA replication. *J Virol.*
444 2010;84:773–787.
- 445 6. **Carpp LN, Rogers RS, Moritz RL, Aitchison JD.** Quantitative proteomic analysis of
446 host-virus interactions reveals a role for Golgi brefeldin A resistance factor 1 (GBF1)
447 in dengue infection. *Mol Cell Proteomics.* 2014;13:2836–2854.
- 448 7. **Farhat R, Ankavay M, Lebsir N, Gouttenoire J, Jackson CL, et al.** Identification of
449 GBF1 as a cellular factor required for hepatitis E virus RNA replication. *Cell*
450 *Microbiol.* 2018;20:e12804.
- 451 8. **Claude A, Zhao BP, Kuziemyky CE, Dahan S, Berger SJ, et al.** GBF1: A novel
452 Golgi-associated BFA-resistant guanine nucleotide exchange factor that displays
453 specificity for ADP-ribosylation factor 5. *J Cell Biol.* 1999;146:71–84.
- 454 9. **Donaldson JG, Jackson CL.** ARF family G proteins and their regulators: roles in
455 membrane transport, development and disease. *Nat Rev Mol Cell Biol.* 2011;12:362–
456 375.
- 457 10. **Wright J, Kahn RA, Sztul E.** Regulating the large Sec7 ARF guanine nucleotide
458 exchange factors: the when, where and how of activation. *Cell Mol Life Sci.*
459 2014;71:3419–3438.
- 460 11. **Bui QT, Golinelli-Cohen M-P, Jackson CL.** Large Arf1 guanine nucleotide exchange
461 factors: evolution, domain structure, and roles in membrane trafficking and human
462 disease. *Mol Genet Genomics.* 2009;282:329–350.
- 463 12. **Szul T, Grabski R, Lyons S, Morohashi Y, Shestopal S, et al.** Dissecting the role of
464 the ARF guanine nucleotide exchange factor GBF1 in Golgi biogenesis and protein
465 trafficking. *J Cell Sci.* 2007;120:3929–3940.
- 466 13. **Bouvet S, Golinelli-Cohen M-P, Contremoulins V, Jackson CL.** Targeting of the

- 467 Arf-GEF GBF1 to lipid droplets and Golgi membranes. *J Cell Sci.* 2013;126:4794–
468 4805.
- 469 14. **Richards AL, Soares-Martins JAP, Riddell GT, Jackson WT.** Generation of unique
470 poliovirus RNA replication organelles. *MBio.* 2014;5:e00833–13.
- 471 15. **Gazina EV, Mackenzie JM, Gorrell RJ, Anderson DA.** Differential requirements for
472 COPI coats in formation of replication complexes among three genera of
473 Picornaviridae. *J Virol.* 2002;76:11113–11122.
- 474 16. **Cherry S, Kunte A, Wang H, Coyne C, Rawson RB et al.** COPI activity coupled
475 with fatty acid biosynthesis is required for viral replication. *PLoS Pathog.* 2006;2:e102.
- 476 17. **Tai AW, Benita Y, Peng LF, Kim S-S, Sakamoto N, et al.** A Functional Genomic
477 Screen Identifies Cellular Cofactors of Hepatitis C Virus Replication. *Cell Host*
478 *Microbe.* 2009;5:298–307.
- 479 18. **Wang J, Wu Z, Jin Q.** COPI is required for enterovirus 71 replication. *PLoS ONE.*
480 2012;7:e38035.
- 481 19. **de Wilde AH, Wansee KF, Scholte FEM, Goeman JJ, Dijke ten P, et al.** A
482 Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host
483 Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including
484 Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway
485 Proteins. *J Virol.* 2015;89:8318–8333.
- 486 20. **Belov GA, Altan-Bonnet N, Kovtunovych G, Jackson CL, Lippincott-Schwartz J,**
487 **et al.** Hijacking components of the cellular secretory pathway for replication of
488 poliovirus RNA. *J Virol.* 2007;81:558–567.
- 489 21. **Matto M, Sklan EH, David N, Melamed-Book N, Casanova JE, et al.** Role for ADP
490 Ribosylation Factor 1 in the Regulation of Hepatitis C Virus Replication. *J Virol.*
491 2011;85:946–956.
- 492 22. **Belov GA, Kovtunovych G, Jackson CL, Ehrenfeld E.** Poliovirus replication
493 requires the N-terminus but not the catalytic Sec7 domain of ArfGEF GBF1. *Cell*
494 *Microbiol.* 2010;12:1463–1479.
- 495 23. **Farhat R, Séron K, Ferlin J, Fénéant L, Belouzard S, et al.** Identification of class II
496 ADP-ribosylation factors as cellular factors required for hepatitis C virus replication.
497 *Cell Microbiol.* 2016;18:1121–1133.
- 498 24. **Farhat R, Goueslain L, Wychowski C, Belouzard S, Fénéant L, et al.** Hepatitis C
499 virus replication and Golgi function in brefeldin a-resistant hepatoma-derived cells.
500 *PLoS ONE.* 2013;8:e74491.
- 501 25. **Renault L, Guibert B, Cherfils J.** Structural snapshots of the mechanism and
502 inhibition of a guanine nucleotide exchange factor. *Nature.* 2003;426:525–530.
- 503 26. **Sáenz JB, Sun WJ, Chang JW, Li J, Bursulaya B, et al.** Golgicide A reveals
504 essential roles for GBF1 in Golgi assembly and function. *Nat Chem Biol.* 2009;5:157–
505 165.

- 506 27. **Volpicelli-Daley LA, Li Y, Zhang C-J, Kahn RA.** Isoform-selective effects of the
507 depletion of ADP-ribosylation factors 1-5 on membrane traffic. *Mol Biol Cell.*
508 2005;16:4495–4508.
- 509 28. **Kudelko M, Brault J-B, Kwok K, Li MY, Pardigon N, et al.** Class II ADP-
510 ribosylation factors are required for efficient secretion of dengue viruses. *J Biol Chem.*
511 2012;287:767–777.
- 512 29. **Iglesias NG, Mondotte JA, Byk LA, De Maio FA, Samsa MM, et al.** Dengue Virus
513 Uses a Non-Canonical Function of the Host GBF1-Arf-COPI System for Capsid
514 Protein Accumulation on Lipid Droplets. *Traffic.* 2015;16:962–977.
- 515 30. **Reiling JH, Olive AJ, Sanyal S, Carette JE, Brummelkamp TR, et al.** A CREB3-
516 ARF4 signalling pathway mediates the response to Golgi stress and susceptibility to
517 pathogens. *Nat Cell Biol.* 2013;15:1473–1485.
- 518 31. **Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, et al.** Formation
519 and intracellular localization of hepatitis C virus envelope glycoprotein complexes
520 expressed by recombinant vaccinia and Sindbis viruses. *J Virol.* 1994;68:6147–6160.
- 521 32. **Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J.** Growth of human
522 hepatoma cells lines with differentiated functions in chemically defined medium.
523 *Cancer Res.* 1982;42:3858–3863.
- 524 33. **Duvet S, Chirat F, Mir AM, Verbert A, Dubuisson J, et al.** Reciprocal relationship
525 between alpha1,2 mannosidase processing and reglucosylation in the rough
526 endoplasmic reticulum of Man-P-Dol deficient cells. *Eur J Biochem.* 2000;267:1146–
527 1152.
- 528 34. **Thiel V, Herold J, Schelle B, Siddell SG.** Infectious RNA transcribed in vitro from a
529 cDNA copy of the human coronavirus genome cloned in vaccinia virus. *J Gen Virol.*
530 2001;82:1273–1281.
- 531 35. **Engelmann I, Alidjinou EK, Bertin A, Bossu J, Villenet C, et al.** Persistent
532 coxsackievirus B4 infection induces microRNA dysregulation in human pancreatic
533 cells. *Cell Mol Life Sci.* 2017;74:3851–3861.
- 534 36. **Rouillé Y, Helle F, Delgrange D, Roingeard P, Voisset C, et al.** Subcellular
535 localization of hepatitis C virus structural proteins in a cell culture system that
536 efficiently replicates the virus. *J Virol.* 2006;80:2832–2841.
- 537 37. **Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, et al.** Genome engineering using
538 the CRISPR-Cas9 system. *Nat Protoc.* 2013;8:2281–2308.
- 539
540

541 **FIGURE LEGENDS**

542 **Figure 1. Brefeldin A sensitivity of viral infections.** (a) Huh-7 cells were infected in the
543 presence of indicated BFA concentrations. Infections were quantified by immunofluorescence
544 assay and expressed as percentage of controls with no BFA. Error bars represent the standard
545 deviation for 3 independent experiments. (b) Huh-7 cells were incubated with indicated BFA
546 concentrations for 6h (BFA 6h) or for 8h followed by 22h without BFA (BFA 8h / DMEM
547 22h), and cell viability was assessed using an MTS assay. Error bars represent the standard
548 deviation for 3 independent experiments. *, **, and *** mean p-values below .05, .01, and
549 .001, respectively.

550

551 **Figure 2. GBF1 requirement for viral infections.** (a) R1 cells were infected in the presence
552 of indicated BFA concentrations. Infections were quantified by immunofluorescence assay
553 and expressed as percentage of controls with no BFA. Error bars represent the standard
554 deviation for 3 independent experiments. (b) Huh-7 cells were infected in the presence of 50
555 μ M GCA or 0.1% DMSO. Infections were quantified by immunofluorescence assay and
556 expressed as percentage of DMSO controls. Error bars represent the standard deviation for 3
557 independent experiments. (c) Huh-7 cells were incubated with indicated GCA concentrations
558 for 6h (GCA 6h) or for 8h followed by 22h without GCA (GCA 8h / DMEM 22h), and cell
559 viability was assessed using an MTS assay. Error bars represent the standard deviation for 3
560 independent experiments. *, **, and *** mean p-values below .05, .01, and .001, respectively.

561

562 **Figure 3. Brefeldin A inhibits a post-entry step.** Huh-7 cells were infected in the presence
563 of 1 μ g/ml BFA or 0.02% DMSO during (entry) and/or after (post-entry) virus inoculation, as
564 indicated. Infections were quantified by immunofluorescence assay and expressed as
565 percentage of controls with no BFA. The data are the means of 2 independent experiments.

566

567 **Figure 4. Impact of siRNA-mediated Arf depletion on viral infections.** (a) Specificity of
568 anti-Arf mAbs probed on lysates of Huh-7 cells expressing the proteins indicated above the
569 blots. (b, c) Specificity of siRNA-mediated depletions. Huh-7 cells were transfected with
570 indicated siRNAs. Arf proteins expression was monitored by immunoblotting at 3 days post-
571 transfection (b), and the bands were quantified (c). Results are expressed as percentages of
572 control non-targeting (siNT1) siRNA. Error bars represent the standard deviation for 3
573 independent experiments. (d, e) Huh-7 cells were transfected with indicated siRNAs (d) or
574 siRNA pairs (e) and infected at 3 days post-transfection. Infections were quantified by
575 immunofluorescence assay and expressed as percentage of control siNT1-transfected cells.
576 Error bars represent the standard deviation for 6 independent experiments. (f) Cell viability of
577 siRNA-transfected Huh-7 cells probed at 3 days post-transfection using an MTS assay and
578 expressed as a percentage of control siNT1-transfected cells. Error bars represent the standard
579 deviation for 3 independent experiments. *, **, and *** mean p-values below .05, .01, and
580 .001, respectively. (g) Huh-7 cells were transfected with indicated siRNA pairs and infected
581 with CVB4 at 3 days post-transfection. The expression of VP1, Arf proteins and tubulin was
582 monitored by immunoblotting.

583

584 **Figure 5. Viral infections of ArfKO cell lines.** Arf5KO (5.1), Arf4KO (4.1) and Arf1KO
585 (1.1; 1.2 and 1.3) cell lines were generated using the CRISPR-Cas9 technology. A control cell
586 line was generated with no sgRNA. (a, b) Arf proteins expression was monitored by
587 immunoblotting (a) and the bands were quantified (b). Results are expressed as percentages
588 relative to the control cell line. The data are the means of 2 independent experiments. (c) KO
589 cells were infected with indicated viruses. Infection were quantified by immunofluorescence

590 assay and expressed as percentage of control KO cells. The data are the means of 2
591 independent experiments.

592

593 **Figure 6. Impact of siRNA-mediated Arf4 depletion in Arf5KO cells on viral infections.**

594 Control and Arf5KO cell lines were transfected with siRNAs to Arf4 or Arf5 or control non-
595 targeting siNT1. At 3 days post-transfection, (a) the cell viability was measured using an
596 MTS assay, (b) Arf4 and Arf5 expression was monitored by immunoblotting, and (c) the cells
597 were infected with indicated viruses. Infections were quantified by immunofluorescence assay
598 and expressed as percentage of control siRNA (NT1)-transfected control cells. Error bars
599 represent the standard deviation for 3 independent experiments. *, **, and *** mean p-values
600 below .05, .01, and .001, respectively.

601




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6